ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer

  • Unal, Dilek (Department of Radiation Oncology, Kayseri Education and Research Hospital) ;
  • Eroglu, Celalettin (Department of Radiation Oncology, Erciyes University Medical School) ;
  • Kurtul, Neslihan (Department of Radiation Oncology, Erciyes University Medical School) ;
  • Oguz, Arzu (Department of Medical Oncology, Kayseri Education and Research Hospital) ;
  • Tasdemir, Arzu (Department of Pathology, Kayseri Education and Research Hospital) ;
  • Kaplan, Bunyamin (Department of Radiation Oncology, Erciyes University Medical School)
  • 발행 : 2013.06.30


Background: Lung cancer is the leading cause of cancer death, late diagnosis being the main obstacle to improving the outcomes with stage at diagnosis as an important prognostic factor. Relationships between ABO blood groups and risk of benign or malignant diseases have been observed and in this study, we aimed to investigate whether they might affect prognosis and response to chemoradiotherapy in patients with local advanced non-small cell lung cancer (NSCLC). Materials and Methods: Eighty-one patients with non-metastatic local advanced NSCLC were included in the study. ABO blood groups were A in 45 (55.6%), B in 7 (8.6%), AB in 8 (9.9%), and O in 21 (25.9%) patients. The patients were also divided two groups according to blood group A (45 patients) and non-A (B, AB and O; 36 patients). Response to chemoradiotherapy was complete remission in 10 (12.3%), disease regression in 42 (51.9%), stable disease in 12 (14.8%), and disease progression in 17 (21.0%) patients. Results: There was no significant difference among ABO blood group categories or between patients with A blood group and those with non-A blood group in terms of responses to chemoradiotherapy (p>0.05). There were also no significant differences regarding overall and disease-free survival rates. Conclusion: The ABO blood group system has no significant effect on prognosis and response to chemoradiotherapy in patients with non-metastatic NSCLC.


  1. Aberle DR, Adams AM, Berg CD, et al (2011). Reduced lung cancer mortality with low-dose computed tomography screening. N Engl J Med, 365, 395-409.
  2. Aird I, Bentall HH, Roberts JA (1953). A relationship between cancer of stomach and the ABO blood groups. Br Med J, 1, 799-801.
  3. Engin H, Bilir C, Ustun H, Gokmen A (2012). ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac J Cancer Prev, 13, 131-3.
  4. Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986). Long-term survivors in metastatic non-small cell lung cancer: an Eastern cooperative oncology group study. J Clin Oncol, 4, 702-9.
  5. Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ (1997). Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res, 3, 87-93.
  6. Greer JB, Yazer MH, Raval JS, et al (2010). Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol, 16, 5588-91.
  7. Hosoi E (2008). Biological and clinical aspects of ABO blood group system. J Med Invest, 55, 174-82.
  8. Kos FT, Civelek B, Seker MM, et al (2012). Is there an association between blood group and survival in pancreatic cancer? Asian Pac J Cancer Prev, 13, 6151-3.
  9. Kuemmel A, Single K, Bittinger F, et al (2007). The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol, 28, 340-9.
  10. Landsteiner K (1900). Zur Kenntnis der antifermentativen, lytischen and agglutinierenden Wirkungen des Blutserums und der Lymphe. Zentralbl Bakteriol, 27, 357-62.
  11. Lee JS, Ro JY, Sahin AA, et al (1991). Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med, 324, 1084-90.
  12. Leon-Atance P, Moreno-Mata N, González-Aragoneses F, et al (2012). Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer. Arch Bronconeumol, 48, 49-54.
  13. Modak H, Kulkarni SS, Kadakol GS, et al (2011). Prevalence and risk of leukemia in the multi-ethnic population of North Karnataka. Asian Pac J Cancer Prev, 12, 671-5.
  14. Melzer D, Perry JR, Hernandez D, et al (2008). A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet, 4, 1000072.
  15. Mohandas N, Narla A (2005). Blood group antigens in health and disease. Curr Opin Hematol, 12, 135-40.
  16. Oguz A, Unal D, Tasdemir A, et al (2013). Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac J Cancer Prev, 14, 453-6.
  17. Pare G, Chasman DI, Kellogg M, et al (2008). Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet, 4, 1000118.
  18. Qian Q, Zhan P, Sun WK, et al (2012). Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma, 59, 433-9.
  19. Urun Y, Ozdemir NY, Utkan G, et al (2012). ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma. Asian Pac J Cancer Prev, 13, 6097-100.
  20. Utkan G, Urun Y, Cangir AK, et al (2013). Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. Asian Pac J Cancer Prev, 14, 249-53.
  21. Wolpin BM, Chan AT, Hartge P, et al (2009). ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31.
  22. Yu JA, Sadaria MR, Meng X, et al (2012). Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase $A_2$ inhibition. J Thorac Cardiovasc Surg, 143, 405-11.
  23. Yuzhalin AE, Kutikhin AG (2012). ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev, 13, 5091-6.
  24. Zmijewski CM (1978). Immunohematology 3rd ed: Appleton Century Crofts, New York.

피인용 문헌

  1. Significance of ABO-Rh Blood Groups in Response and Prognosis in Breast Cancer Patients Treated with Radiotherapy and Chemotherapy vol.15, pp.9, 2014,
  2. Impact of ABO blood group on the prognosis of patients undergoing surgery for esophageal cancer vol.15, pp.1, 2015,
  3. The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy vol.33, pp.11, 2015,
  4. Relationship between ABO blood group and clinicopathological factors and their effect on the survival of Japanese patients with esophageal squamous cell carcinoma vol.47, pp.8, 2017,